What is prognosis of Breast cancer?

['Sel i usebter-agi']

Amek yettwaḥsab umdan ma yuḍen s ukansir n tebbuct?

Asugen n ukansir n tebbuct yerza agmuḍ yettwarǧan neɣ tikli i d-yettbanen n waṭṭan.

Yettwaḥsab s umata s yimgan am aswir n kunsir, ṣṣenf n kunsir, leɛmer d tezmert tameqqrant n umuḍin, d tneflit n usafar.

Akken yettwaf kan s zzerb uḍḍan n tebbuct u yettwaḥla, i tgerrez tmuɣli.

Azal n tudert n xemsa iseggasen i yimuḍinen n ukansir n tebbuct yezzi ar 90%, anamek-is 90% n yimuḍinen yettwaḍḍfen s ukansir n tebbuct mazal-iten ddren xemsa iseggasen mbeɛd mi d-yettwaḍḍef.

D acu kan, yelha ad neẓer belli yal liḥala n yal amdan weḥd-s, dɣa asugen yezmer ad yemgarad s waṭas ɣef leḥsab n tegnatin tinmettitin.

['Tiɣbula']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

McCarthy AM, Manning AK, Hsu S, Welch M, Moy B, Lehman CD, Armstrong K: Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer. Breast Cancer Res Treat. 2022, 196 (2): 389-398.

Han Y, Wang J, Xu B: Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. Breast. 2020, 54 (): 114-120.

Wang Z, Chen J, Zhong MZ, Huang J, Hu YP, Feng DY, Zhou ZJ, Luo X, Liu ZQ, Jiang WZ, Zhou WB: Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients. Cancer Chemother Pharmacol. 2017, 79 (3): 535-543.

Zhang L, Han L, Huang Y, Feng Z, Wang X, Li H, Song F, Liu L, Li J, Zheng H, Wang P, Song F, Chen K: SNPs within microRNA binding sites and the prognosis of breast cancer. Aging (Albany NY). 2021, 13 (5): 7465-7480.

Li Y, Duan W, Qi Q, Wang T, Yang Q, Du L, Mao H, Wang C: A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer. Cell Death Dis. 2021, 12 (7): 670.

Li N, Li Z, Li X, Chen B, Sun H, Zhao K: Identification of an immune-related long noncoding RNA signature that predicts prognosis in breast cancer patients. Biomark Med. 2021, 15 (3): 167-180.

['Anfafad: amejjay']

['Asmel-a web yettunefk-d kan i yiswiyen n uselmed d usissen, ur d-yettak ara iwellihen imejjayen neɣ isefka udmawanen.']

['Isallen i d-yettunefken ur ilaq ara ad ttwasqedcen i usebded neɣ i usemḥi n kra n wugur n tezmert neɣ aṭṭan, yerna wid yettnadin ɣef yiwellihen imsujjiyen udmawanen yessefk ad ẓren amejjay yesɛan turagt.']

['Ttxil-k ẓer belli azeṭṭa amseddayan i d-yettaken tiririyin i tuttriwin, ur iṣeḥḥa ara mliḥ ma yella d ayen yerzan uḍḍun. D amedya, amḍan n yimdanen yettwaḍḍfen s kra n waṭṭan.']

['Ssutur dima ṛṛay n ṭṭbib-ik neɣ n kra n umejjay-nniḍen ara iwalmen ɣef waṭṭan-ik. Ɣur-k ad tḥeqreḍ ṛṛay n ṭṭbib amsadur neɣ ad tεeṭṭleḍ deg usuter-is ɣef lǧal n kra i teɣriḍ deg usmel-a. Ma tɣileḍ ahat tesεiḍ liḥala n tεeǧlanit deg tezmert, siwel 911 neɣ ṛuḥ ɣer texxamt n tεeǧlanit i d-iqerben. Ulac assaɣ gar ṭṭbib d umuḍin i d-yettnulfun s usmel-a neɣ aseqdec-is. BioMedLib neɣ ixeddamen-is, neɣ kra n win yettekkiyen deg usmel-a, ur d-ttaken ara yakk kra n yisumren, s wawal neɣ s usemres, ɣef ayen yerzan isallen i d-yettunefken dagi neɣ aseqdec-is.']

['Anekcum: azref n uḍfar']

['Asaḍuf n umeskar n yizerfan n wemdan n alfin (Digital Millennium Copyright Act) n 1998, 17 U.S.C. § 512 (DMCA) yettak-d ttawil i yimeskaren n yizerfan n wemdan i yumnen belli ayen i d-yettbanen deg Internet yettḍurru izerfan-nsen ddaw usaḍuf n umeskar n yizerfan n wemdan n Marikan. ']

['Ma tumneḍ s wul yelhan belli kra n taɣult neɣ taɣawsa yettwafken deg unermes-nneɣ neɣ deg yiqeddacen-nneɣ tegzem azref-ik n uḥraz, tzemreḍ (neɣ amsedday-ik) ad aɣ-d-tazneḍ izen akken ad nessuter asuffeɣ n taɣult neɣ n taɣawsa-nni, neɣ ad nessader tuqqna ɣer-s. ']

['Isental yessefk ad ttwazen s tira s yimayl (ẓer asebter "Contact" i tansa n yimayl).']

['DMCA teḥwaǧ isalli-inek n tukksa n yizerfan yettwanekṛen ad d-yeglu s yisallen-a: (1) asegzi n umahil yettwaḥerzen s yizerfan yettwanekṛen i d-yettwanekren; (2) asegzi n uḍris yettwanekren d yisallen ara aɣ-yeǧǧen ad d-naf uḍris-nni; (3) isallen n usiwel inek, ladɣa tansa-inek, uṭṭun n tilifun d tansa imayl; (4) awal sɣur-k d akken tumneḍ s wayen yelhan belli aḍris-nni s wamek i d-tettcetkiḍ ur yettwasemres ara sɣur bab n yizerfan, neɣ amesten-is, neɣ s useqdec n kra n usaḍuf; ']

['(5) yiwet n tseddi sɣur-k, yettwatten s uḥasef n lekdeb, d akken isallen yellan deg uzenzi d iṣeḥḥan u tesεiḍ azref ad tesseḍruḍ izerfan umeskar i d-yeqqaren ttwarẓen; ']

['akked (6) azmul n tfekka neɣ n tuqqna tagensit n bab n yizerfan neɣ n umdan yettwafernen ad yexdem s yisem n bab n yizerfan. ']

['Ma ur d-terriḍ ara isallen-agi akk, yezmer ad d-yeglu s uεeṭṭel deg usefrek n ucetki-inek.']

['Assaɣ']

['Ttxil-k azen-aɣ-d imayl ma tesεiḍ asteqsi / asumer.']

What is prognosis of breast cancer?

The prognosis of breast cancer refers to the predicted outcome or likely course of the disease.

It is typically determined by factors such as the stage of the cancer, the type of cancer, the patient's age and overall health, and the effectiveness of treatment.

The earlier breast cancer is detected and treated, the better the prognosis tends to be.

The five-year survival rate for breast cancer patients is around 90%, meaning that 90% of patients diagnosed with breast cancer are still alive five years after their diagnosis.

However, it is important to note that every individual's situation is unique, and the prognosis can vary greatly depending on the specific circumstances.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.